| 1771 |
LUCIPOMA |
POMALIDOMIDE 4 MG |
CAPSULE |
BOTTLE |
FOR THE TREATMENT OF ADULT PATIENTS: IN COMBINATION WITH DEXAMETHASONE, FOR PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 2 PRIOR THERAPIES INCLUDING LENALIDOMIDE AND PROTEASOME INHIBITOR AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETEION OF LAST THERAPY |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
12 L 1283/24 |
23-JAN-2025 |
22-JAN-2030 |
View |
| 1772 |
LUCIPONA |
PONATINIB 15 MG |
TABLET |
BOTTLE |
TREATMENT OF ADULT PATIENT WITH: CHRONIC PHASE CHRONIC MYELOID LEUKEMIA WITH RESISTANCE OR INTOLERANCE TO AT LEAST TWO PRIOR KINASE INHIBITOR |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
04 L 1090/24 |
08-APR-2024 |
07-APR-2027 |
View |
| 1773 |
LUCIPONA |
PONATINIB 45 MG |
TABLET |
BOTTLE |
TREATMENT OF ADULT PATIENT WITH: CHRONIC PHASE CHRONIC MYELOID LEUKEMIA WITH RESISTANCE OR INTOLERANCE TO AT LEAST TWO PRIOR KINASE INHIBITOR |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
04 L 1092/24 |
08-APR-2024 |
07-APR-2027 |
View |
| 1774 |
LUCIPRAL |
PRALSETINIB 100 MG |
CAPSULE |
BOTTLE |
TREAMENT OF NON SMALL CELL LUNG CANCER |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
08 I 1007/23 |
29-AUG-2023 |
28-AUG-2026 |
View |
| 1775 |
LUCIPRET |
PRETOMANID 200 MG |
TABLET |
BOTTLE |
AS PART OF A COMBINATION REGIMEN WITH BEDAQUILINE AND LINEZOLID FOR THE TREATMENT OFADULTS WITH PULMONARY EXTENSIVELY DRUG RESISTANT, TREATMENT INTOLERANT OR NONRESPONSIVE MULTIDRUG RESISTANT TUBERCULOSIS. |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
04 L 1342/25 |
27-MAY-2025 |
26-MAY-2030 |
View |
| 1776 |
LUCIQUIZA |
QUIZARTINIB 17.7 MG |
TABLET |
BOTTLE |
IN COMBINATION WITH STANDARD CYTARABINE AND ANTHRACYCLINE INDUCTION AD CYTARABINE CONSOLIDATION, AND AS MAINTENANCE MONOTHERAPY FOLLOWING CONSOLIDATION CHEMOTHERAPY, FOR THE TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA THAT IS FLT3 INTERNAL TANDERM DUPLICATION POSITIVE. |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
06 L 1105/24 |
21-JUN-2024 |
20 JUN 2027 |
View |
| 1777 |
LUCIQUIZA |
QUIZARTINIB 26.5 MG |
TABLET |
BOTTLE |
IN COMBINATION WITH STANDARD CYTARABINE AND ANTHRACYCLINE INDUCTION AD CYTARABINE CONSOLIDATION, AND AS MAINTENANCE MONOTHERAPY FOLLOWING CONSOLIDATION CHEMOTHERAPY, FOR THE TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA THAT IS FLT3 INTERNAL TANDERM DUPLICATION POSITIVE. |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
06 L 1106/24 |
21-JUN-2024 |
20 JUN 2027 |
View |
| 1778 |
LUCIREPO |
REPOTRECTINIB 40 MG |
CAPSULE |
BOTTLE |
FOR THE TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ROS1-POSITIVE NON SMALL CELL LUNG CANCER |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
02 L 1071/24 |
14-MAR-2023 |
13-MAR-2027 |
View |
| 1779 |
LUCIRES |
RESMETIROM 60 MG |
TABLET |
BOTTLE |
IN CONJUNCTION WITH DIET AND EXCERCISE FOR THE TREATMENT OF ADULT WITH NONCIRRHOTIC STEATOHEPATITIS WITH MODERATE TO ADVANCED LIVER FIBROSIS |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
09 L 1195/24 |
24-SEP-2024 |
23-SEP-2029 |
View |
| 1780 |
LUCIRES |
RESMETIROM 80 MG |
TABLET |
BOTTLE |
IN CONJUNCTION WITH DIET AND EXCERCISE FOR THE TREATMENT OF ADULT WITH NONCIRRHOTIC STEATOHEPATITIS WITH MODERATE TO ADVANCED LIVER FIBROSIS |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
09 L 1192/24 |
24-SEP-2024 |
23-SEP-2029 |
View |
